|
|
Volumn 17, Issue 7, 2018, Pages 465-466
|
|
The global landscape of cancer cell therapy
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AXICABTAGENE CILOLEUCEL;
BB 2121;
CANCER VACCINE;
CHIMERIC ANTIGEN RECEPTOR;
IMMUNCELL LC;
IMMUNICELL;
LISOCABTAGENE MARALEUCEL;
NALOTIMAGENE CARMALEUCEL;
NICORD;
NIVOLUMAB;
PEMBROLIZUMAB;
TABLECLEUCEL;
TISAGENLECLEUCEL T;
TT 10;
TUMOR ANTIGEN;
UNCLASSIFIED DRUG;
ACUTE LYMPHOBLASTIC LEUKEMIA;
B CELL LEUKEMIA;
B CELL LYMPHOMA;
CELL THERAPY;
CHRONIC MYELOID LEUKEMIA;
CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT;
DIFFUSE LARGE B CELL LYMPHOMA;
EPSTEIN BARR VIRUS INFECTION;
FOLLICULAR LYMPHOMA;
GLOBAL HEALTH;
HUMAN;
LARGE CELL LYMPHOMA;
LEUKEMIA;
LIVER CANCER;
MALIGNANT NEOPLASM;
MANDATORY REPORTING;
MELANOMA;
MULTIPLE MYELOMA;
MYELODYSPLASTIC SYNDROME;
NASOPHARYNX CARCINOMA;
NON SMALL CELL LUNG CANCER;
NONHODGKIN LYMPHOMA;
PLURIPOTENT STEM CELL;
POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE;
PRIMARY MEDIASTINAL B CELL LYMPHOMA;
PRIORITY JOURNAL;
REFERENCE VALUE;
RENAL CELL CARCINOMA;
SHORT SURVEY;
STAKEHOLDER ENGAGEMENT;
STATISTICAL BIAS;
STATISTICAL DISTRIBUTION;
TARGET CELL;
BIOLOGICAL THERAPY;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
NEOPLASM;
PROCEDURES;
CELL- AND TISSUE-BASED THERAPY;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
HUMANS;
NEOPLASMS;
|
|
EID: 85049252670
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd.2018.74 Document Type: Short Survey |
|
Times cited : (66)
|
|
References (0)
|
